2013-04-25 07:30:00 CEST
2013-04-25 07:30:41 CEST
SÄÄNNELTY TIETO
Oriola-KD Oyj - Interim report (Q1 and Q3)
Oriola-KD Corporation's Interim Report for 1 January - 31 March 2013
Oriola-KD Corporation Stock Exchange Release 25 April 2013 at 8.30 a.m.
Financial performance January-March 2013
* Net sales increased by 3.6 per cent to EUR 612.3 (590.8) million.
* Operating profit was EUR 2.3 (5.2) million.
* Net cash flow from operations was EUR -26.1 (-27.1) million.
* Profit for the period came to EUR 0.7 (1.3) million and earnings per share
were EUR 0.00 (0.01).
* Return on equity was 0.9 (1.7) per cent.
Key figures 2013 2012 Change 2012
EUR million Jan-Mar Jan-Mar % Jan-Dec
---------------------------------------------------------------
Net sales 612.3 590.8 3.6% 2,474.4
Operating profit excluding
non-recurring items* 2.3 5.2 -55.3% 26.8
Operating profit 2.3 5.2 -55.3% 25.8
Profit for the period 0.7 1.3 -46.3% 16.4
Earnings per share, EUR 0.00 0.01 -46.3% 0.11
Net cash flow from operations -26.1 -27.1 46.1
Return on equity (ROE), % 0.9 1.7 5.4
Gearing ratio, end of period, % 12.6 17.5 2.1
*) Year 2012: operating profit excluding non-recurring items of a receivable
write-off of EUR 1.1 million in Sweden.
Outlook for 2013
* Oriola-KD estimates that net sales and operating profit excluding non-
recurring items will increase from 2012 level. Growth of the net sales of
Pharmaceutical Trade Russia will slow down in the first part of the year and
operating profit will be weaker than the previous year, as a result of
challenges related to the implementation of the warehouse management system
started in January 2013.
President and CEO Eero Hautaniemi's comments regarding the interim report:"Oriola-KD's net sales increased by 3.6 per cent to EUR 612.3 and operating
profit came to EUR 2.3 million in January-March 2013. Pharmaceutical Trade
Sweden's operating profit improved from EUR 3.4 million to EUR 3.8 million while
Pharmaceutical Trade Russia's operating loss grew from EUR 1.1 million to EUR
3.6 million. In the review period, the operating profit of the Swedish retail
business grew as a result of growth in the relative share of sales of parallel
imports, the OTC assortment and traded goods. The performance of the Russian
retail business continued to improve and the business recorded an operating
profit. Operating profit for the first quarter declined especially because of
the increased operating loss of the Russian wholesale business caused by
delivery problems associated with the implementation of the warehouse management
system. Also, the operating profit of the Swedish wholesale business decreased
as a result of costs from the launch of centralised purchasing, warehousing and
pharmacy distribution of OTC products and traded goods. During the review
period, business in Finland and the Baltics developed mainly as planned. In
addition, the consolidated operating profit for the first quarter was reduced by
a EUR 1.0 million expenses associated with acquisition in Sweden."
Oriola-KD Corporation's Interim Report for 1 January - 31 March 2013
The text section of this financial statements release focuses on the January-
March result. A comparison in accordance with the International Financial
Reporting Standards (IFRS) has been carried out on the figures for the
corresponding period in 2012, unless otherwise stated. The figures in this
interim report are unaudited. The figures in the tables have been rounded
independently.
The Group's net sales and result for January-March 2013
The Oriola-KD Group's (hereinafter Oriola-KD) net sales in January-March 2013
increased by 3.6 per cent to EUR 612.3 (590.8) million. Pharmaceutical Trade
Sweden's net sales grew by 5.7 per cent to EUR 273.7 (258.9) million and
Pharmaceutical Trade Russia's net sales grew by 7.4 per cent to EUR 231.1
(215.2) million. The net sales of Pharmaceutical Trade Finland and Baltics
decreased by 7.9 per cent to EUR 107.5 (116.8) million.
Oriola-KD's operating profit for January-March decreased by 55.3 per cent to EUR
2.3 (5.2) million. The operating profit of the Pharmaceutical Trade Sweden grew
by 9.7 per cent to EUR 3.8 (3.4) million. The operating profit of Pharmaceutical
Trade Finland and Baltics grew by 3.6 per cent to EUR 4.8 (4.6) million. The
operating loss of Pharmaceutical Trade Russia grew from EUR 1.1 million to EUR
3.6 million. The operating profit of the Swedish retail business grew in the
review period as a result of growth in the relative share of sales of parallel
imports, the OTC assortment and traded goods. The Russian retail business
recorded an operating profit for January-March 2013. The first quarter profit
was held back by the increased operating loss of the Russian wholesale business
caused by delivery difficulties in the Moscow region associated with the
implementation of the warehouse management system, while the decline in
operating profit in the Swedish wholesale business was a result of the continued
increase of the share of parallel imports and generic medicines. Also, costs
from the launch of a centralised purchasing, warehousing and pharmacy
distribution of OTC products and traded goods had a negative impact on the
operating profit of the Swedish wholesale business. The profitability of the
Finnish wholesale business improved during the review period as a result of
improvements in operating efficiency and growth in service sales. During the
first quarter, the profitability of the Consumer Health business was affected by
a low customer flow at pharmacies and investments in the development of strong
brands. During the review period, business in the Baltics developed as planned.
In addition, the consolidated operating profit for the first quarter was reduced
by a EUR 1.0 million expense associated with acquisition in Sweden.
Profit after financial items was EUR 0.9 (2.5) million and profit for the period
was EUR 0.7 (1.3) million. Oriola-KD's financial expenses decreased to EUR 1.4
(2.7) million, due to lower interest expenses and a EUR 0.7 million accrual cost
of an arrangement fee for a loan repaid in connection with the renewal of bank
loans with an impact on 2012 financial items. Earnings per share were EUR 0.00
(EUR 0.01).
Return on equity was 0.9 (1.7) per cent in January-March 2013.
The figures for the comparison year have been adjusted due to a revision of the
calculation method for pension liabilities (IAS 19R (revision) Employee
benefits). The impact has been itemised under Revision of the IAS 19 standard
Employee benefits.
Reporting segments
Oriola-KD's reporting segments are Pharmaceutical Trade Finland and Baltics,
Pharmaceutical Trade Sweden and Pharmaceutical Trade Russia. Oriola-KD has
formed its reporting segments by combining its operating segments. The
Pharmaceutical Trade Finland and Baltics reporting segment comprises the Finnish
pharmaceutical wholesale business, the Consumer Health and the Pharmaceutical
Trade Baltics operating segments. The Pharmaceutical Trade Sweden reporting
segment comprises the Swedish pharmaceutical retail and Swedish pharmaceutical
wholesale operating segments. The Pharmaceutical Trade Russia reporting segment
comprises the Russian pharmaceutical retail and Russian pharmaceutical wholesale
operating segments.
Pharmaceutical Trade Finland and Baltics
Key figures 2013 2012 Change 2012
EUR million Jan-Mar Jan-Mar % Jan-Dec
------------------------------------------------------------------
Net sales 107.5 116.8 -7.9% 460.5
Finnish wholesale 86.4 96.6 -10.5% 380.7
Baltics wholesale 10.4 8.8 17.6% 36.1
Consumer Health 10.9 11.5 -5.4% 44.2
Operating profit 4.8 4.6 3.6% 20.8
Personnel at the end of the period 470 503 476
January-March 2013
The net sales of Pharmaceutical Trade Finland and Baltics in January-March 2013
were EUR 107.5 (116.8 ) million and operating profit was EUR 4.8 (4.6) million.
Invoicing of the wholesale business in Finland came to EUR 255.1 (256.2) million
and net sales came to EUR 86.4 (96.6) million. Net sales of the wholesale
business in the Baltic countries were EUR 10.4 (8.8) million and net sales of
the Consumer Health business, i.e. consumer health products sold under Oriola-
KD's own brands or exclusive sales rights, were EUR 10.9 (11.5) million. The
profitability of the Finnish wholesale business improved as a result of
improvements in operating efficiency and growth in service sales. The
profitability of the Consumer Health business was affected in the first quarter
by a low customer flow at pharmacies and investments in developing the product
assortment. During the review period, business in the Baltics developed as
planned. The warehousing and distribution of Novartis' products has been
centralised in Latvia for all Baltic countries since February 2013.
Oriola-KD and Merck Sharp & Dohme (MSD) have signed an agreement on the
marketing and distribution of medicines in the Baltic countries. Under the
agreement Oriola-KD will distribute and market MSD's medicines in Estonia,
Lithuania and Latvia. MSD's sales and marketing personnel in Estonia, Latvia and
Lithuania will transfer to Oriola-KD in May 2013. The distribution of MSD's
medicines in all Baltic countries will be centralised to Oriola-KD's warehouse
in Lithuania as of September 2013. MSD will continue to be in charge of
marketing authorisation and product strategy including market access, medical
affairs and clinical research in the Baltic countries.
The Finnish pharmaceutical market grew by 1.0 (3.9) per cent in January-March
2013. The decrease in pharmaceutical reimbursements and the 5 per cent cut in
the wholesale prices of patented pharmaceuticals in February 2013 had a negative
impact on the growth of the pharmaceutical market in Finland. Oriola-KD's market
share of the Finnish pharmaceutical wholesale market was 47.3 (47.1) per cent in
January-March 2013. The distribution of AstraZeneca's products by Oriola-KD will
be discontinued in 2013. AstraZeneca's market share was roughly 3.2 per cent in
March 2013. (source: IMS Health)
Pharmaceutical Trade Finland and Baltics had 470 (503) employees at the end of
March 2013.
Pharmaceutical Trade Sweden
Key figures 2013 2012 Change 2012
EUR million Jan-Mar Jan-Mar % Jan-Dec
------------------------------------------------------------------------------
Net sales 273.7 258.9 5.7% 1,061.3
Retail trade 131.9 124.8 5.7% 502.5
Wholesale trade 183.0 147.4 24.2% 636.7
Operating profit excluding non-recurring items 3.8 3.4 9.7% 16.2
Operating profit 3.8 3.4 9.7% 15.1
Personnel at the end of the period 1,291 1,232 1,324
Retail trade 1,014 991 1,064
Wholesale trade 277 241 260
January-March 2013
The net sales of Pharmaceutical Trade Sweden in January-March 2013 were EUR
273.7 (258.9) million and operating profit was EUR 3.8 (3.4) million. Invoicing
of the wholesale business came to EUR 382.8 (338.5) million and net sales came
to EUR 183.0 (147.4) million. The net sales of the wholesale business were
increased by the centralised purchasing, warehousing and pharmacy distribution
of OTC products and traded goods to five pharmacy chains. Net sales of the
retail business were EUR 131.9 (124.8) million.
The operating profit of the retail business grew as a result of growth in the
relative share of sales of parallel imports, the OTC assortment and traded
goods. The retail market of OTC products and traded goods products increased
5.8 (3.8) per cent in January-March 2013 (source: Nielsen). In the first
quarter, Oriola-KD opened 3 (3) pharmacies and at the end of March, there were a
total of 222 (212) Kronans Droghandel pharmacies.
The continued growth in the share of parallel imports and generic
pharmaceuticals weakened the net sales and operating profit of the wholesale
business. Costs from the launch of centralised purchasing, warehousing and
pharmacy distribution of OTC products and traded goods had a continued negative
impact in the first quarter of 2013. The ramp-up of the centralised purchasing,
warehousing and pharmacy distribution was completed by the end of the first
quarter.
The pharmaceutical market decreased by 4.2 (grew 2.0) per cent in January-March
2013. Oriola-KD's market share of the pharmaceutical wholesale market was 34.5
(36.9) per cent and 13.4 (13.5) per cent of the retail market in January-March
2013 (source: IMS Health). There were no pharmacy bankruptcies in the Swedish
pharmacy market in the review period. In the period, 9 new pharmacies were
opened (1 closed) in the Swedish pharmacy market.
Pharmaceutical Trade Sweden had 1,291 (1,232) employees at the end of March
2013, 1,014 (991) of whom were employed in retail and 277 (241) in wholesale.
Pharmaceutical Trade Russia
Key figures 2013 2012 Change 2012
EUR million Jan-Mar Jan-Mar % Jan-Dec
------------------------------------------------------------------
Net sales 231.1 215.2 7.4% 952.7
Retail 39.8 37.3 6.8% 148.6
Wholesale 194.7 184.5 5.5% 831.1
Operating profit -3.6 -1.1 232.9% -2.3
Personnel at the end of the period 3,048 3,048 3,056
Retail 1,326 1,382 1,309
Wholesale 1,722 1,666 1,747
January-March 2013
The net sales of Pharmaceutical Trade Russia in January-March 2013 were EUR
231.1 (215.2) million and operating loss was EUR 3.6 (operating loss 1.1)
million. Net sales of the wholesale business in Russia were 194.7 (184.5)
million and net sales of the retail business were EUR 39.8 (37.3) million.
Oriola-KD has booked EUR 0.2 million in accelerated depreciation from the
current main logistics centre in Moscow for the first quarter.
The retail business made an operating profit in January-March 2013. The sales of
traded goods and pharmacy-specific sales grew on the previous year and the cost
structure continued to improve. At the end of March 2013, Oriola-KD had 239
(243) pharmacies in the Moscow area, of which 168 (174) operated under the Stary
Lekar brand and 71 (69) under the 03 Apteka brand. During January-March 2013, 1
(3) pharmacy was opened and 2 (9) pharmacies were closed.
The growth of net sales from the wholesale business slowed and operating loss
increased due to difficulties with deliveries in the Moscow region associated
with the implementation of the warehouse management system. Deliveries in
January-March 2013 in the Moscow region declined temporarily by some 50 per cent
on the comparison period. The net sales of the distribution centres outside
Moscow continued to grow as planned in January-March 2013. In accordance with
its customer credit policy, Oriola-KD has booked EUR 0.1 (0.3) million credit
loss write-offs relating to the trade receivables in January-March 2013.
Monitoring of customers' terms of payment and the collection of trade
receivables has been intensified in order to minimise credit loss risks. Oriola-
KD has signed a letter of intent on a 10-year lease agreement to transfer a new
main logistics centre in Moscow region and on the logistics centre's automation
solution. The project has been continued according to plan in the first quarter
of 2013.
The ruble-denominated growth in the Russian pharmaceutical market was about
20.5 (4.5) per cent in January-March 2013 (source: IMS Health). Net sales of
Oriola-KD's retail business increased by 8.4 (10.8) per cent while the increase
in wholesale was 7.1 (30.8) per cent in Russian rubles in January-March 2013.
Oriola-KD's net sales grew by 9.0 (31.0) per cent in Russian rubles in the same
period.
Pharmaceutical Trade Russia had 3,048 (3,048) employees at the end of March
2013, of whom 1,326 (1,382) were employed in retail and 1,722 (1,666) in
wholesale.
Non-recurring items
A non-recurring item is an income or expense arising from non-recurring or rare
events. Gains or losses from the sale of business operations or assets, gains or
losses from discontinuing or restructuring business operations as well as
impairment losses of goodwill and other assets are recognised as non-recurring
items.
No non-recurring items were recognised in the first quarter of 2013. A non-
recurring item of a receivable write-off of EUR 1.1 million associated with the
bankruptcy of a Swedish cash transport company was recognised in the Swedish
retail company in the third quarter of 2012.
Balance sheet, financing and cash flow
Oriola-KD's balance sheet total on 31 March 2013 stood at EUR 1,331.9 (1,212.8)
million. Cash assets were EUR 83.4 (71.3) million, equity was EUR 304.2 (297.9)
million and the equity ratio was 23.4 (25.0) per cent.
Oriola-KD's group goodwill of EUR 283.0 million has been allocated in impairment
testing to the cash-generating units consisting of the Group's operating
segments. EUR 119.9 million of the goodwill was allocated to the Swedish
pharmaceutical retail business, EUR 28.5 million to the Swedish pharmaceutical
wholesale business, EUR 90.2 million to the Russian pharmaceutical wholesale
business and EUR 44.4 million to the Russian pharmaceutical retail business.
Interest-bearing debt at the end of March 2013 was EUR 121.9 (123.4) million,
interest-bearing net debt was EUR 38.5 (52.1) million and the gearing ratio was
12.6 (17.5) per cent. Interest-bearing debt consisted mainly of the use of the
issued commercial paper programme and advance payments from pharmacies in
Finland. The non-recourse trade receivables sales programmes related to monthly
trade receivables from Swedish county councils and Apoteket AB were continued in
the retail and wholesale businesses in Sweden in the first quarter of 2013. At
the end of March 2013, a total of EUR 68.0 (56.6) million in trade receivables
had been sold.
Oriola-KD's committed long-term credit facility of EUR 100.0 million and EUR
43.9 million of short-term credit account limits with banks were unused at the
end of March 2013. A total of EUR 89.5 (85.7) million of Oriola-KD's EUR 150.0
million commercial paper programme was in use at the end of the review period.
Net cash flow from operations in January-March 2013 was EUR -26.1 (-27.1)
million, of which changes in working capital accounted for EUR -30.6 (-33.1)
million. Net cash flow from operations was EUR -6.0 (-4.6) million.
Investments
Gross investments for January-March 2013 came to EUR 5.8 (4.3) million and
consisted of investments related to the opening of new pharmacies, information
systems and improvements in logistics efficiency. As per plan, Oriola-KD has
booked EUR 0.2 million in accelerated depreciation due to the investment plan
for the logistics centre in Moscow in the first quarter of 2013.
Personnel and Group Management Team
On 31 March 2013, Oriola-KD had a payroll of 4,809 (4,783) employees, 10 (11)
per cent of whom worked in Finland and the Baltic countries, 27 (26) per cent in
Sweden, and 63 (63) per cent in Russia. Personnel numbers include the members of
staff in active employment.
Changes to the Oriola-KD Group Management Team: Jukka Mäkelä, M.Sc. (b. 1963),
has been appointed Vice President, Development of Oriola-KD Corporation and
member of Oriola-KD's Group Management Team as of 1 April 2013.
Oriola-KD's Group Management Team as of 1 April 2013:
* Eero Hautaniemi, President and CEO
* Lars Birkeland, Vice President, pharmaceutical retail, Sweden
* Henry Fogels, Vice President, pharmaceutical wholesale, Russia
* Tuomas Itkonen, CFO
* Konstantin Minin, Vice President, pharmaceutical retail, Russia
* Jukka Mäkelä, Vice President, Development
* Teija Silver, Vice President, HR
* Kimmo Virtanen, Executive Vice President and Vice President, Pharmaceutical
Wholesale, Finland, Sweden and the Baltics
Related parties
Related parties in the Oriola-KD Group are deemed to comprise the members of the
Board of Directors and the President and CEO of Oriola-KD Corporation, the other
members of the Group Management Team of the Oriola-KD Group, the immediate
family of the aforementioned persons, the companies controlled by the
aforementioned persons, and the Oriola Pension Fund. The Group has no
significant business transactions with related parties, except for pension
expenses arising from defined benefit plans with the Oriola Pension Fund.
Oriola-KD Corporation shares
Trading volume of the Oriola-KD Corporation's class A and B shares in January-
March 2013:
Trading volume January-March 2013 January-March 2012
class A class B class A class B
Trading volume, million 0.6 8.3 1.7 10.9
Trading volume, EUR million 1.5 19.9 3.5 21.2
Highest price, EUR 2.69 2.73 2.20 2.15
Lowest price, EUR 2.25 2.24 1.85 1.73
Closing quotation, end of period, EUR 2.42 2.46 1.92 1.87
Oriola-KD Corporation's market capitalisation on 31 March 2013 was EUR 370.2
(285.2) million.
In the review period, the traded volume of Oriola-KD Corporation shares,
excluding treasury shares, corresponded to 5.9 (8.4) per cent of the total
number of shares. The traded volume of class A shares amounted to 1.3 (3.7) per
cent of the average stock, and that of class B shares, excluding treasury
shares, 8.0 (10.5) per cent of the average stock.
At the end of March 2013, the company had a total of 151,257,828 (151,257,828)
shares, of which 47,148,710 (47,148,710) were class A shares and 104,109,118
(104.109.118) were class B shares. The company has 96,822 treasury shares, all
of which are class B shares. These account for 0.06 per cent of the company's
shares and 0.009 per cent of the votes.
Under Article 3 of the Articles of Association, a shareholder may demand
conversion of class A shares into class B shares. During the period 1 January -
31 March 2013, no class A shares were converted into class B shares (0 shares).
On 19 December 2012, Oriola-KD Corporation's Board of Directors decided on a new
share incentive scheme for the Group's senior management for the years
2013-2015. The company's Board of Directors will determine the earnings criteria
for the earning period and the targets to be set for these at the start of each
earning period. The bonus for the 2013 earning period is based on the Oriola-KD
Group's earnings per share (EPS) and return on capital employed (ROCE). Oriola-
KD Corporation is also planning to set up a share savings plan for 70 of the
Group's key employees. The Board of Directors of Oriola-KD Corporation is aiming
to make the final decision regarding the plan in spring 2013.
Decisions of the Annual General Meeting
The Annual General Meeting of Oriola-KD Corporation, held on 20 March 2013,
adopted the 2012 financial statements and discharged the members of the Board of
Directors and the President and CEO from liability for the financial year ending
31 December 2012.
The AGM decided to distribute EUR 0.05 per share in dividend on the 2012
financial year, coming to a total of EUR 7.6 million, and EUR 0.04 per share in
repayment of equity, coming to a total of EUR 6.0 million.
The AGM confirmed that the Board comprises six members. Jukka Alho, Harry Brade,
Per Båtelson, Outi Raitasuo and Mika Vidgrén were re-elected as Board members
and Karsten Slotte was elected as a new member. Jukka Alho was elected to as
Chairman of the Board. The AGM confirmed a term of office fee of EUR 48,400 for
the Chairman of the Board, EUR 30,250 for the Vice Chairman and for the chairman
of the Audit Committee, and EUR 24,200 each for the other members of the Board.
The Chairman receives an attendance fee of EUR 800 per meeting, and the other
Board members EUR 400 per meeting. Attendance fees will also be paid in the same
manner to members of any committees set up by the Board of Directors or the
company. Of the annual fees, 60 per cent will be paid in cash and 40 per cent
will be used to acquire Oriola-KD Corporation class B shares for the Board
members on the Helsinki stock exchange within two weeks of the publication of
the Oriola-KD Corporation interim report for 1 January - 31 March 2013.
PricewaterhouseCoopers Oy was re-elected as auditor for the company, with Heikki
Lassila APA as principal auditor.
The AGM authorised the Board to decide on repurchasing up to fifteen million of
the company's own class B shares. Shares may be repurchased also in a proportion
other than in which shares are owned by the shareholders. The authorisation is
in force for eighteen months following the decision of the AGM.
The AGM authorised the Board to decide on a share issue against payment in one
or more issues, including the right to issue new class B shares or to assign
class B shares held by the company. The authorisation covers a combined maximum
of thirty million class B shares of the company and includes the right to
derogate from the shareholders' pre-emptive subscription right. The
authorisation is in force for eighteen months following the decision of the AGM.
The Board was also authorised to decide on a bonus issue of class B shares to
the company in one or more issues, and on a directed issue of class B shares to
implement the new share incentive scheme of the Oriola-KD Group's management and
the share savings plan for its key employees. The maximum amount of the
company's new B class shares issued under this authorisation is 1,715,000, which
is 1.13 per cent of the company's total shares. The authorisation will remain in
force for a maximum of 5 years following the decision of the AGM.
At its constitutive meeting held immediately after the AGM, the Board of Oriola-
KD Corporation elected Outi Raitasuo as Vice Chairman of the Board. The Board of
Directors appointed the following from among its members: Outi Raitasuo
(Chairman), Harry Brade, Karsten Slotte and Mika Vidgrén to the Board's Audit
Committee, and Jukka Alho (Chairman), Per Båtelson and Harry Brade to the
Board's Remuneration Committee. The Board of Directors has assessed the
independence of its members and determined that all members are independent of
both the company and its major shareholders.
Risks
Oriola-KD's Board of Directors has approved the company's risk management policy
in which the risk management operating model, principles, responsibilities and
reporting are specified. The Group's risk management seeks to identify, measure
and manage risks that may threaten Oriola-KD's operations and the achievement of
goals set. The roles and responsibilities relating to risk management have been
determined in the Group.
Oriola-KD's risks are classified as strategic, operational and financial. Risk
management is a key element of the strategic process, operational planning and
daily decision-making at Oriola-KD.
Oriola-KD has identified the following principal strategic and operational risks
in its business:
* Amendments to pharmaceutical market regulations may weaken Oriola-KD's
profitability.
* In the Swedish retail business, the free establishment of pharmacies has led
to increase in the number of pharmacies. The number of pharmacies may
continue to grow, which could further increase the fierce competition.
* In the Russian retail business, tough competition resulting from the large
number of pharmacies may lead to a further decrease in the gross margin and
a rapid turnover rate of key personnel.
* Extra capacity ensuing from a change in the Swedish wholesale market will
intensify competition, which may weaken the profitability of operations. The
share of single channel distribution in the pharmaceutical wholesale market
may decline rapidly, which may weaken the profitability of operations and
lead to the restructuring of wholesale operations.
* As a result of the tough competition in the Russian wholesale business, the
gross margin may decline further, which will lead to a continued need to
intensify operations and restructure wholesale operations over the long
term. The payment behaviour that is typical to the Russian market, combined
with the regional expansion of operations may increase credit risks.
* Strategic development projects involve operational risks.
The major financial risks for Oriola-KD involve currency rate, liquidity,
interest rate and credit risks. Currency risks are the most significant
financial risks in Russia and Sweden, as any changes in the value of the Russian
ruble and the Swedish krona will have an impact on Oriola-KD's earnings and
equity.
Goodwill and intangible rights are subject to impairment testing at least once
every year. Changes in cash flow forecasts based on strategic plans, or in the
discount rate or perpetuity growth rate, can cause a goodwill write-off, which
would weaken Oriola-KD's result. The impairment test of the goodwill of the
Russian cash-generating units, in particular, is sensitive to changes in the
discount rate or cash-flow forecasts.
Near-term risks and uncertainty factors
A decrease in gross margin resulting from intense competition and an increase in
credit risks concerning customers may have an impact on the profitability of the
wholesale business in Russia. Oriola-KD's strategic development projects in the
wholesale business in Russia and the operations in Sweden involve operational
risks which may have an effect on Oriola-KD's profitability.
Outlook
Oriola-KD's outlook for 2013 is based on external market forecasts, agreements
with pharmaceutical companies and pharmacies, and management assessments. In the
period 2012-2016, the pharmaceutical market is expected to grow on average per
year by 0.3 per cent in Finland, 0.5 per cent in Sweden, and 11.1 per cent in
Russia, measured in local currencies (source: IMS Health).
Oriola-KD estimates that net sales and operating profit excluding non-recurring
items will increase from 2012 level. Growth of the net sales of Pharmaceutical
Trade Russia will slow down in the first part of the year and operating profit
will be weaker than the previous year, as a result of challenges related to the
implementation of the warehouse management system started in January 2013.
Events after the review period
On 8 April 2013, Oriola-KD announced that it had signed an agreement to acquire
the entire capital stock of Sweden's fifth largest pharmacy chain Medstop Group
Holding AB ("Medstop") from Segulah Management IV Limited. The total value of
the acquisition is approximately SEK 1,460 million (EUR 176 million), comprising
three separate items: a SEK 680 million (EUR 82 million) cash acquisition price,
the net debt of the acquired company and a conditional earn-out payment payable
on the basis of the consolidated 2015 EBITDA of Oriola-KD's combined Swedish
Retail business. Oriola-KD will finance the acquisition in full with a bank
loan. The deal is expected to be concluded in the second quarter of 2013 and is
subject to the approval of the Swedish Competition Authority (Konkurrensverket)
and the Swedish Medical Products Agency (Läkemedelsverket).
The Medstop pharmacy chain has a total of 65 pharmacies located in shopping
centres and city centre locations in the Stockholm, Gothenburg and Malmö areas.
Its net sales were EUR 273 (299) million and EBITDA was EUR 11.6 (11.5) million
excluding non-recurring items. The EBITDA is approximately 4.2 (3.8) per cent of
net sales. At the end of 2012, the net debt of the pharmacy chain was EUR 75
(80) million and its balance sheet total was EUR 215 (223) million. Medstop's
market share was approximately 7.5 per cent of the Swedish pharmacy market at
the end of 2012. The chain employed 578 persons at the end of 2012.
According to the decisions of the Annual General Meeting, the company paid a
dividend of EUR 0.05 per share, totalling EUR 7.6 million, and distributed EUR
0.04 per share as repayment of equity, totalling EUR 6.0 million, on 12 April
2013.
Next interim report
Oriola-KD Corporation will publish its results for the second quarter of 2013 on
Thursday 25 July 2013 at about 8.30 am.
Oriola-KD's Interim Report for January - March 2013
Consolidated Statement of
Comprehensive Income (IFRS), 1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
EUR million 2013 2012 2012
-------------------------------------------------------------------------------
Net sales 612.3 590.8 2,474.4
Cost of goods sold -524.9 -504.8 -2,117.8
-------------------------------------------------------------------------------
Gross profit 87.5 86.0 356.6
Other operating income 2.0 0.5 2.3
Selling and
distribution expenses -72.0 -67.4 -277.1
Administrative expenses -15.2 -13.9 -54.9
-------------------------------------------------------------------------------
Operating Profit before Non-
recurring items * 2.3 5.2 26.8
Non-recurring items** - - -1.1
-------------------------------------------------------------------------------
Operating Profit 2.3 5.2 25.8
Financial income 3.8 2.0 22.7
Financial expenses -5.2 -4.7 -28.0
-------------------------------------------------------------------------------
Profit before taxes 0.9 2.5 20.5
Income taxes *** -0.3 -1.2 -4.1
-------------------------------------------------------------------------------
Profit for the period 0.7 1.3 16.4
Other comprehensive income
Cash flow hedge 0.5 0.0 -0.9
Actuarial gains/losses on
defined benefit plan - - 1.6
Income tax relating to
other comprehensive income -0.2 0.8 -0.6
Translation difference 6.3 13.4 11.4
-------------------------------------------------------------------------------
Total comprehensive income
for the period 7.3 15.5 27.9
Attribution of Profit for the
period
-------------------------------------------------------------------------------
To parent company shareholders 0.7 1.3 16.4
-------------------------------------------------------------------------------
Attribution of total
comprehensive
income for the period
-------------------------------------------------------------------------------
To parent company shareholders 7.3 15.5 27.9
-------------------------------------------------------------------------------
Earnings per share for the period
Basic earnings per share, EUR 0.00 0.01 0.11
Diluted earnings per share, EUR 0.00 0.01 0.11
*) Including depreciation, EUR
million -5.1 -4.4 -18.8
**) Receivable write-off in
Sweden Q3/2012 - - -1.1
***) The tax expense for the
period
corresponds to the taxes
calculated from the
profit for the financial period
Consolidated Balance Sheet
(IFRS),
EUR million
ASSETS 31 Mar 2013 31 Mar 2012 31 Dec 2012
-------------------------------------------------------------------------------
Non-current assets
Property, plant and equipment 84.8 75.1 81.4
Goodwill 283.0 277.5 276.7
Other intangible assets 52.1 52.1 52.3
Other shares and shareholdings 0.0 0.0 0.0
Other non-current assets 6.4 4.3 6.6
Deferred tax assets 6.5 7.3 6.1
-------------------------------------------------------------------------------
Non-current assets total 433.0 416.4 423.1
Current assets
Inventories 393.1 354.3 389.8
Trade and other receivables 422.4 370.8 415.2
Cash and cash equivalents 83.4 71.3 88.1
-------------------------------------------------------------------------------
898.9 796.3 893.1
Non-current assets held for sale 0.0 0.0 0.0
-------------------------------------------------------------------------------
Current assets total 899.0 796.4 893.1
ASSETS TOTAL 1,331.9 1,212.8 1,316.2
-------------------------------------------------------------------------------
EQUITY AND LIABILITIES 31 Mar 2013 31 Mar 2012 31 Dec 2012
-------------------------------------------------------------------------------
Equity of the parent
company shareholders
Share capital 36.2 36.2 36.2
Funds 20.3 26.7 26.0
Other equity 247.7 235.1 248.4
-------------------------------------------------------------------------------
Equity total 304.2 297.9 310.5
Non-current liabilities
Deferred tax liabilities 14.2 14.2 14.1
Pension obligations 10.0 7.8 9.7
Borrowings 0.4 15.2 0.4
Other non-current liabilities 0.5 - 1.0
-------------------------------------------------------------------------------
Non-current liabilities total 25.1 37.2 25.2
Current liabilities
Trade payables and other current
liabilities 881.1 769.4 886.1
Borrowings 121.5 108.2 94.3
-------------------------------------------------------------------------------
Current liabilities total 1,002.6 877.7 980.5
EQUITY AND LIABILITIES TOTAL 1,331.9 1,212.8 1,316.2
-------------------------------------------------------------------------------
Consolidated
Statement
of Changes in
Equity (IFRS)
Equity of the parent
company shareholders
Trans-
Contin lation Actuarial
Share Hedge gency Other diffe- gains/ Retained Equity
EUR million capital fund fund funds rences losses earnings total
-------------------------------------------------------------------------------
Equity
31 Dec 2011 36.2 -0.0 30.0 1.2 -7.2 - 239.1 299.3
-------------------------------------------------------------------------------
Change in
accounting
policy (IAS19) - - - - - -4.8 - -4.8
-------------------------------------------------------------------------------
Equity
1 Jan 2012 36.2 -0.0 30.0 1.2 -7.2 -4.8 239.1 294.5
-------------------------------------------------------------------------------
Comprehensive
income for the
period
Net profit
for the period - - - - - - 1.3 1.3
Other
comprehensive
income:
Cash flow
hedge - 0.0 - - - - - 0.0
Income tax
relating to
other
comprehensive
income - - - - 0.8 - - 0.8
Translation
difference - - - - 13.4 - - 13.4
-------------------------------------------------------------------------------
Comprehensive
income for the
period total - 0.0 - - 14.1 - 1.3 15.5
-------------------------------------------------------------------------------
Owners related
transactions
Dividends
paid and return
of equity -4.5 - -7.6 -12.1
Share-based
payments - - - - - - 0.1 0.1
-------------------------------------------------------------------------------
Owners related
transactions
total - - -4.5 - - - -7.5 -12.0
-------------------------------------------------------------------------------
Equity
31 Mar 2012 36.2 - 25.5 1.2 7.0 -4.8 232.9 297.9
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Equity
31 Dec 2012 36.2 -0.7 25.5 1.2 3.9 - 248.9 314.9
-------------------------------------------------------------------------------
Change in
accounting
policy (IAS19) - - - - -0.0 -3.6 -0.8 -4.4
-------------------------------------------------------------------------------
Equity
1 Jan 2013 36.2 -0.7 25.5 1.2 3.8 -3.6 248.1 310.5
-------------------------------------------------------------------------------
Comprehensive
income for the
period
Net profit
for the period - - - - - - 0.7 0.7
Other
comprehensive
income:
Cash flow
hedge - 0.5 - - - - - 0.5
Income tax
relating to
other
comprehensive
income - -0.1 - - -0.1 - - -0.2
Translation
difference - -0.0 - - 6.3 - - 6.3
-------------------------------------------------------------------------------
Comprehensive
income for the
period total - 0.4 - - 6.2 - 0.7 7.3
-------------------------------------------------------------------------------
Owners related
transactions
Dividends
paid and return
of equity - - -6.0 - - - -7.6 -13.6
Share-based
payments - - - - - - 0.0 0.0
-------------------------------------------------------------------------------
Owners related
transactions
total - - -6.0 - - - -7.5 -13.6
-------------------------------------------------------------------------------
Equity
31 Mar 2013 36.2 -0.3 19.4 1.2 10.0 -3.6 241.3 304.2
-------------------------------------------------------------------------------
Consolidated Cash Flow Statement 1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
(IFRS), EUR million 2013 2012 2012
-------------------------------------------------------------------------------
Operating profit 2.3 5.2 25.8
Depreciation 5.1 4.4 18.8
Impairment - - -
Change in working capital -30.6 -33.1 23.1
Cash flow from financial
items and taxes -1.8 -3.0 -20.3
Other adjustments -1.1 -0.6 -1.2
Net cash flow from operating
activities -26.1 -27.1 46.1
Net cash flow from investing
activities -6.0 -4.6 -34.9
Net cash flow from financing
activities 27.2 -51.3 -77.3
Net change in cash and cash
equivalents -4.9 -83.0 -66.2
Cash and cash equivalents
at the beginning of the period 88.1 153.8 153.8
Foreign exchange rate differences 0.2 0.5 0.4
Net change in cash and cash
equivalents -4.9 -83.0 -66.2
Cash and cash equivalents
at the end of the period 83.4 71.3 88.1
-------------------------------------------------------------------------------
Principal accounting policies as of 1 January 2013 (IFRS)
This interim report has been prepared in accordance with IFRS standards (IAS
34). The accounting policies and calculation methods applied in the interim
report are the same as those in the 31 December 2012 annual financial
statements, excluding the standards and interpretation applied as of 1 January
2013 and presented below. However, the interim report does not include all of
the information and notes present in the annual financial statements.
Consequently, the interim report should be read with the company's financial
statements for 2012. The accounting policies of the 2012 and 2013 financial
years are comparable. The company has not discontinued any operations in 2012 or
2013 that it should report.
The same principles of calculation have been used for the indicators in this
interim report as for those of the annual financial statements.
The figures in the interim report have been rounded independently.
New amendments that have been applied since 1 January 2013:
* Amendment to the standard IAS 12 Income Taxes (effective in financial years
beginning on or after 1 January 2013).
* Amendment to the standard IAS 19R (revised) Employee Benefits (effective in
financial years beginning on or after 1 January 2013).
* IFRS 13 Fair Value Measurement (effective in financial years beginning on or
after 1 January 2013).
The impact of the amendment of standard IAS 19 Employee benefits on the
consolidated result has been itemised below. The amendments of the other new
standards referred to above have had minor impact on the Group.
The figures in this interim review are unaudited.
Amendment of the IAS 19 standard Employee benefits
The Oriola-KD Group has applied the standard IAS 19 Employee benefits as of 1
January 2013. The amendment impacts the Oriola-KD Group's pension costs and
result and the pension assets and obligations and equity on the balance sheet.
As a consequence of the amendment, the 2012 consolidated profit and loss account
and balance sheet have been updated as required by the revised standard.
The key amendments of the standards IAS 19R (revised) Employee benefits are that
all actuarial gains and losses must be recognised immediately in other
comprehensive income and that expected yield from assets no longer depends on
investment distribution. The discount rate used in the calculation of pension
debt is used as the expected yield of investments. The corridor method will no
longer be used and financing expenditure will be the sum of net interest rates.
The net interest rate is the difference between the interest rate costs of
pension debt and the interest rate income from assets. Despite the amendment,
the Group has decided to recognise the sum of net interest rate in personnel
expenses.
With the implementation of the revised standard IAS 19 Employee benefits, the
Oriola-KD Group's operating profit excluding non-recurring items, operating
profit and profit for the financial year 2012 and, on the balance sheet, the
pension assets and equity are smaller and pension obligation is larger than when
calculated in accordance with the standard in force up to 31 December 2012. The
impact of the implementation on consolidated operating profit excluding non-
recurring items and operating profit for 2012 is EUR 1.0 million. The impact on
Group equity on the 2012 opening balance sheet is EUR -4.8 million and EUR -4.4
million on the 31 December 2012 balance sheet due to the recognition of
actuarial gains and losses and their tax effect on equity on the consolidated
balance sheet. The following tables present a summary of the key figures
following the amendment of the accounting policy.
1 Jan- 1 Jan- 1 Jan- 1 Jan-
EUR million 31 Mar 2012 30 Jun 2012 30 Sep 2012 31 Dec 2012
-------------------------------------------------------------------------------
Operating profit excluding
non-recurring items 5.2 9.2 16.4 26.8
Operating profit 5.2 9.2 15.3 25.8
Profit before taxes 2.5 4.5 8.4 20.5
Profit for the period 1.3 2.8 5.0 16.4
Comprehensive profit for the
period 15.5 6.6 17.8 27.9
Earnings per share to
shareholders of
the parent company on the
profit for the period, EUR
Diluted, EUR 0.01 0.02 0.03 0.11
Adjusted for the dilution
effect, EUR 0.01 0.02 0.03 0.11
1 Jan- 1 Apr- 1 July- 1 Oct- 1 Jan-
31 Dec 31 Dec
EUR million 31 Mar 2012 30 Jun 2012 30 Sep 2012 2012 2012
-------------------------------------------------------------------------------
Operating profit
excluding non-
recurring items 5.2 4.0 7.2 10.5 26.8
Operating profit 5.2 4.0 6.2 10.5 25.8
Profit before taxes 2.5 2.0 4.0 12.0 20.5
Profit for the
period 1.3 1.5 2.1 11.4 16.4
Comprehensive profit
for the period 15.5 -8.8 11.2 10.1 27.9
Earnings per share
for shareholders of
the parent company
on the profit for
the period, EUR
Diluted, EUR 0.01 0.01 0.01 0.08 0.11
Adjusted for the
dilution effect, EUR 0.01 0.01 0.01 0.08 0.11
EUR million 31 Mar 2012 30 Jun 2012 30 Sep 2012 31 Dec 2012
-------------------------------------------------------------------------------
Non-current pension assets 4.3 4.1 3.8 6.6
Non-current pension
obligations 7.8 7.9 8.3 9.7
Equity of the parent company's
shareholders 297.9 289.2 300.4 310.5
Notes
Change in Property, Plant and
Equipment, 1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
EUR million 2013 2012 2012
-------------------------------------------------------------------------------
Carrying amount at the beginning
of the period 81.4 74.0 74.0
Increases 5.1 3.3 16.6
Decreases -0.1 -0.3 -0.5
Depreciation -3.0 -2.6 -11.1
Foreign exchange rate differences 1.6 0.6 2.4
-------------------------------------------------------------------------------
Carrying amount at the end of the
period 84.8 75.1 81.4
-------------------------------------------------------------------------------
1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
Key Figures 2013 2012 2012
-------------------------------------------------------------------------------
Equity ratio, % 23.4 25.0 24.5
Equity per share, EUR 2.01 1.97 2.05
Return on capital employed
(ROCE), % 2.2 4.6 5.9
Return on equity (ROE), % 0.9 1.7 5.4
Net interest-bearing debt, EUR
million 38.5 52.1 6.7
Gearing, % 12.6 17.5 2.1
Earnings per share, EUR 0.00 0.01 0.11
Average number of shares, 1000
pcs 151,161 151,161 151,248
Derivatives, Commitments
and Contingent Liabilities
31 March 2013
Positive fair Negative fair Nominal values
EUR million value value of contracts
Derivatives recognised
as cash flow hedges
Interest rate swaps - -0.5 47.9
Derivatives measured at
fair value through profit
and loss
Foreign currency forward
and swap contracts - -1.4 142.9
31 March 2012
Positive fair Negative fair Nominal values
EUR million value value of contracts
Derivatives measured at
fair value through profit
and loss
Foreign currency forward
and swap contracts 0.5 - 191.6
Interest rate swaps - -0.0 113.1
Derivatives measured at fair value through profit and loss are mainly related
to hedging of group's internal transactions. All of the financial instruments
which are measured at fair value are derivatives and have been classified to
level 2 in fair value hierarchy. Fair values of the derivatives have been
booked to balance sheet in gross amount as the derivatives contracts are
related to credit events and cannot be netted in financial statements. The
group has not given nor received collateral to/from derivatives
counterparties.
Contingencies for Own
Liabilities,
EUR million 31 Mar 2013 31 Mar 2012 31 Dec 2012
-------------------------------------------------------------------------------
Guarantees given 19.1 9.6 23.4
Mortgages on land and
buildings - 2.0 2.0
Mortgages on company assets 2.5 2.4 2.4
Other guarantees and
liabilities 0.8 0.7 0.8
-------------------------------------------------------------------------------
Total 22.5 14.7 28.7
-------------------------------------------------------------------------------
Leasing-liabilities
(operating liabilities) 2.4 3.4 2.8
Rent contingencies 66.9 63.9 66.9
The most significant reported guarantees are bank guarantees against trade
payables in wholesale companies in Russia and Sweden. Oriola-KD Corporation
has also granted parent company guarantees of EUR 27.0 million (EUR 18.1
million) against subsidiaries' trade payables.
1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
Number of personnel 2013 2012 2012
-------------------------------------------------------------------------------
Average number of
personnel 4,838 4,835 4,818
Number of personnel at the
end of the period 4,809 4,783 4,856
SEGMENT INFORMATION
1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
Net Sales, EUR million 2013 2012 2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 107.5 116.8 460.5
Pharmaceutical Trade
Sweden 273.7 258.9 1,061.3
Pharmaceutical Trade
Russia 231.1 215.2 952.7
Net sales to other
segments -0.0 -0.0 -0.0
-------------------------------------------------------------------------------
Group total 612.3 590.8 2,474.4
1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
Operating Profit, EUR
million 2013 2012 2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.8 4.6 20.8
Pharmaceutical Trade
Sweden 3.8 3.4 15.1
Pharmaceutical Trade
Russia -3.6 -1.1 -2.3
Group Administration and
Others -2.6 -1.8 -7.8
-------------------------------------------------------------------------------
Group total 2.3 5.2 25.8
Operating Profit excl.
Non-recurring items, 1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
EUR million 2013 2012 2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.8 4.6 20.8
Pharmaceutical Trade
Sweden 3.8 3.4 16.2
Pharmaceutical Trade
Russia -3.6 -1.1 -2.3
Group Administration and
Others -2.6 -1.8 -7.8
-------------------------------------------------------------------------------
Operating Profit excl.
Non-recurring items 2.3 5.2 26.8
Non-recurring items * - - -1.1
-------------------------------------------------------------------------------
Group total 2.3 5.2 25.8
*) EUR -1.1 million
receivable write-off in
Pharmaceutical Trade
Sweden Q3/2012
Quarterly Net Sales, EUR million Q1/2013 Q4/2012 Q3/2012 Q2/2012 Q1/2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 107.5 118.3 108.7 116.6 116.8
Pharmaceutical Trade Sweden 273.7 292.4 254.1 255.9 258.9
Pharmaceutical Trade Russia 231.1 296.9 223.3 217.3 215.2
Net sales to other segments -0.0 0.2 -0.0 -0.1 -0.0
-------------------------------------------------------------------------------
Group total 612.3 707.8 586.1 589.7 590.8
Quarterly Operating Profit, EUR
million Q1/2013 Q4/2012 Q3/2012 Q2/2012 Q1/2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.8 5.2 6.1 4.8 4.6
Pharmaceutical Trade Sweden 3.8 4.6 3.7 3.4 3.4
Pharmaceutical Trade Russia -3.6 3.1 -2.0 -2.2 -1.1
Group Administration and Others -2.6 -2.4 -1.6 -2.0 -1.8
-------------------------------------------------------------------------------
Group total 2.3 10.5 6.2 4.0 5.2
Quarterly Operating Profit,
excl. Non-recurring items, EUR million Q1/2013 Q4/2012 Q3/2012 Q2/2012 Q1/2012
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.8 5.2 6.1 4.8 4.6
Pharmaceutical Trade Sweden 3.8 4.6 4.8 3.4 3.4
Pharmaceutical Trade Russia -3.6 3.1 -2.0 -2.2 -1.1
Group Administration and Others -2.6 -2.4 -1.6 -2.0 -1.8
-------------------------------------------------------------------------------
Group total excl. Non-recurring items 2.3 10.5 7.2 4.0 5.2
Non-recurring items * - - -1.1 - -
-------------------------------------------------------------------------------
Group total 2.3 10.5 6.2 4.0 5.2
*) EUR -1.1 million receivable write-
off in Pharmaceutical Trade Sweden
Q3/2012
1 Jan - 31 Mar 1 Jan - 31 Mar 1 Jan - 31 Dec
Net Sales by Market, EUR million 2013 2012 2012
------------------------------------------------------------------------------
Finland 96.8 107.4 422.4
Sweden 259.0 252.2 1,028.8
Russia 231.1 215.2 952.7
Baltic countries 10.0 8.4 34.6
Other countries 15.4 7.5 35.9
------------------------------------------------------------------------------
Group total 612.3 590.8 2,474.4
Quarterly Net Sales by Market, EUR
million Q1/2013 Q4/2012 Q3/2012 Q2/2012 Q1/2012
-------------------------------------------------------------------------------
Finland 96.8 107.8 99.7 107.6 107.4
Sweden 259.0 282.6 244.7 249.3 252.2
Russia 231.1 296.9 223.3 217.3 215.2
Baltic countries 10.0 9.4 8.6 8.1 8.4
Other countries 15.4 11.0 10.0 7.4 7.5
-------------------------------------------------------------------------------
Group total 612.3 707.8 586.1 589.7 590.8
Espoo, 24 April 2013
Board of Directors of Oriola-KD Corporation
Oriola-KD Corporation
Eero Hautaniemi
President and CEO
Tuomas Itkonen
CFO
Further information:
Eero Hautaniemi
President and CEO
tel. +358 (0)10 429 2109
e-mail: eero.hautaniemi@oriola-kd.com
Tuomas Itkonen
CFO
tel. +358 (0)46 876 5207
e-mail: tuomas.itkonen@oriola-kd.com
Joni Ihantola
Vice President, Treasury and IR
tel. +358 (0)10 429 4386
e-mail: joni.ihantola@oriola-kd.com
Distribution:
NASDAQ OMX Helsinki Ltd
Key media
Released by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
02200 Espoo
www.oriola-kd.com
[HUG#1695840]
© 2024 Nasdaq, Inc. All Rights Reserved |
| Evästeet |